Rizatriptan Shortage: What Providers and Prescribers Need to Know in 2026

Current Availability Status

As of 2026, rizatriptan is not listed on the FDA Drug Shortage Database or the ASHP shortage database. Generic rizatriptan is manufactured by multiple companies and supply chain integrity is intact. Unlike scheduled substances, rizatriptan is not subject to DEA production quotas and can be manufactured in quantities that meet demand.

That said, many patients report access difficulties — difficulties that are driven by insurance barriers, pharmacy stocking patterns, and formulation-specific availability, not by a genuine supply chain disruption. This document is intended to help clinicians understand the practical access landscape and prepare patients accordingly.

Common Barriers Your Patients Are Facing

1. Pharmacy Stocking Issues (ODT vs. Tablet)

The orally disintegrating tablet (ODT) formulation of rizatriptan — preferred by many migraine patients due to nausea — is manufactured by fewer generic companies than the standard tablet. Chain pharmacies with automated, demand-based inventory may not stock the ODT unless prescription volume at that location justifies it.

Clinical implication: If a patient reports their pharmacy is "out" of rizatriptan ODT, consider whether switching them to the standard tablet formulation temporarily is clinically appropriate. For most patients, the standard tablet is equivalent if taken with adequate water at headache onset.

2. Insurance Quantity Limits and Step Therapy

Most commercial and Medicare Part D plans impose quantity limits on all triptans — typically 9 tablets per 30-day period. Medicare Part D lists rizatriptan on Tier 2 with a typical copay of $10–$30 for generic. However, some plans require:

Step therapy: Documentation of a trial with sumatriptan before rizatriptan will be approved

Prior authorization: PA required for any triptan above the quantity limit or for the brand-name version

Non-formulary status: Some narrow formulary plans don't cover rizatriptan at all — patients may need sumatriptan, or an appeal process

Clinical tip: For patients you anticipate will need more than 9 tablets per month (frequent migraines), proactively initiate preventive migraine therapy (e.g., topiramate, amitriptyline, propranolol, or CGRP monoclonal antibodies) to reduce the number of acute treatments needed. This can reduce insurance friction while improving patient outcomes.

3. The Propranolol Interaction: A Prescribing Consideration

Propranolol, commonly prescribed for migraine prevention, inhibits MAO-A, increasing rizatriptan AUC by approximately 70%. In patients receiving propranolol for migraine prophylaxis who also need rizatriptan for acute treatment:

Maximum single dose of rizatriptan: 5 mg (not 10 mg)

Maximum daily dose of rizatriptan: 15 mg (3 doses of 5 mg)

For pediatric patients ≥40 kg on propranolol: single 5 mg dose only, not to exceed 5 mg/24 hr

Ensure this dosing adjustment is clearly communicated on the prescription and that the patient understands the lower dose limit. An alternative acute agent (e.g., sumatriptan, which does not have this interaction with propranolol at standard doses) may be preferable for patients on propranolol who require 10 mg rizatriptan doses for adequate relief.

Formulary Alternatives When Rizatriptan Is Not Accessible

If a patient cannot access rizatriptan due to insurance or pharmacy barriers, the following alternatives are supported by clinical evidence:

Sumatriptan (generic Imitrex): Most widely stocked and lowest cost triptan; available as tablet, nasal spray, and injection; first-line alternative for most patients

Zolmitriptan (generic Zomig): Available in tablet, ODT, and nasal spray; good option for patients needing a non-oral route

Ubrogepant (Ubrelvy) or rimegepant (Nurtec ODT): CGRP receptor antagonists; appropriate for patients with cardiovascular contraindications to triptans; increasingly covered by commercial insurance with PA

Lasmiditan (Reyvow): 5-HT1F agonist; no cardiovascular contraindications; note Schedule V status and 8-hour driving restriction

How medfinder Supports Your Patients

medfinder helps patients find their medications at pharmacies near them. When a patient leaves your office with a prescription for rizatriptan, medfinder can call local pharmacies on their behalf to verify which ones have the medication in stock and can fill the prescription. This reduces the "prescription abandonment" problem, where patients give up trying to fill a medication because they can't locate it. Visit medfinder.com/providers to learn how providers can refer patients to the service.

Clinical Recommendations for Managing Rizatriptan Access

Prescribe the tablet form by default (5 mg or 10 mg); reserve ODT for patients with documented nausea who cannot tolerate tablets

Document propranolol use in all migraine patients and adjust rizatriptan dose accordingly

Verify insurance formulary before prescribing; check whether sumatriptan trial is required

Consider co-prescribing a second triptan as a backup for patients with frequent migraines

Counsel patients on GoodRx/SingleCare coupons as a backup when insurance doesn't cover or monthly limits are exceeded — generic rizatriptan is available for $7-$13 for 9 tablets

Refer patients to medfinder.com/providers to help them locate pharmacies with inventory before or after appointments